News | August 09, 2022
Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The WAVEsystem with the WAVEcontrol 4.0 embedded
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
Subscribe To Our Newsletter & Stay Updated
